Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination

References

• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 2015; 33:23-35; PMID:25621841; http://dx.doi.org/10.1016/j.coi.2015.01.006
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11:509-24; PMID:25001465; http://dx.doi.org/10.1038/nrclinonc.2014.111
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22:929-79; PMID:15032600; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104622
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10:170-81; PMID:20154735; http://dx.doi.org/10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223:114-31; PMID:18613832; http://dx.doi.org/10.1111/j.1600-065X.2008.00635.x
   PubMed Web of Science ®Google Scholar
• Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12:1301-9; PMID:17041596; http://dx.doi.org/10.1038/nm1492
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765; PMID:11244051; http://dx.doi.org/10.1146/annurev.immunol.19.1.683
   PubMed Web of Science ®Google Scholar
• Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, Ram Z, Orenstein A, Kershenovich A, Michowiz S et al. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004; 64:1843-52; PMID:14996748; http://dx.doi.org/10.1158/0008-5472.CAN-03-3179
   PubMed Web of Science ®Google Scholar
• Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008; 180:3797-806; PMID:18322186; http://dx.doi.org/10.4049/jimmunol.180.6.3797
   PubMed Web of Science ®Google Scholar
• Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, Seder RA. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 2010; 207:1421-33; PMID:20530206; http://dx.doi.org/10.1084/jem.20092532
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004; 199:775-84. Epub 2004 Mar 8; PMID:15007094; http://dx.doi.org/10.1084/jem.20031591
   PubMed Web of Science ®Google Scholar
• Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 2007; 67:7945-7; PMID:17804699; http://dx.doi.org/10.1158/0008-5472.CAN-07-1652
   PubMed Web of Science ®Google Scholar
• Wells JW, Cowled CJ, Farzaneh F, Noble A. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 2008; 181:3422-31; PMID:18714014; http://dx.doi.org/10.4049/jimmunol.181.5.3422
   PubMed Web of Science ®Google Scholar
• Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011; 71:5467-76; PMID:21730023; http://dx.doi.org/10.1158/0008-5472.CAN-10-3988
   PubMed Web of Science ®Google Scholar
• Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157:231-8; PMID:8683120
   PubMed Web of Science ®Google Scholar
• Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184:579-84; PMID:8760811; http://dx.doi.org/10.1084/jem.184.2.579
   PubMed Web of Science ®Google Scholar
• Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011; 20:781-96; PMID:22172723; http://dx.doi.org/10.1016/j.ccr.2011.11.003
   PubMed Web of Science ®Google Scholar
• Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, Zou W. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012; 72:420-9; PMID:22123924; http://dx.doi.org/10.1158/0008-5472.CAN-10-4627
   PubMed Web of Science ®Google Scholar
• Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160:3188-93; PMID:9531274
   PubMed Web of Science ®Google Scholar
• Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol 2003; 24:36-43; PMID:12495723; http://dx.doi.org/10.1016/S1471-4906(02)00009-1
   PubMed Web of Science ®Google Scholar
• Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001; 103:449-57; PMID:11529935; http://dx.doi.org/10.1046/j.1365-2567.2001.01279.x
   PubMed Web of Science ®Google Scholar
• Bouabe H, Liu Y, Moser M, Bosl MR, Heesemann J. Novel highly sensitive IL-10-beta-lactamase reporter mouse reveals cells of the innate immune system as a substantial source of IL-10 in vivo. J Immunol 2011; 187:3165-76; PMID:21844394; http://dx.doi.org/10.4049/jimmunol.1101477
   PubMed Web of Science ®Google Scholar
• Diaz-Valdes N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JI, Borras-Cuesta F, Sarobe P, Feijoo E. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2011; 71:812-21; PMID:21159663; http://dx.doi.org/10.1158/0008-5472.CAN-10-2698
   PubMed Web of Science ®Google Scholar
• Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004; 4:9; PMID:15384929
   PubMedGoogle Scholar
• Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181:776-84; PMID:18566444; http://dx.doi.org/10.4049/jimmunol.181.1.776
   PubMed Web of Science ®Google Scholar
• Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69:917-27; PMID:19267352; http://dx.doi.org/10.1002/pros.20941
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kundig TM et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol 2012; 42:3049-61; PMID:22806397; http://dx.doi.org/10.1002/eji.201142361
   PubMed Web of Science ®Google Scholar
• Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010; 184:5360-7; PMID:20308630; http://dx.doi.org/10.4049/jimmunol.0902997
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L, Lin CT, Wu TC. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 2003; 10:1311-20; PMID:12883527; http://dx.doi.org/10.1038/sj.gt.3301982
   PubMed Web of Science ®Google Scholar
• Bolpetti A, Silva JS, Villa LL, Lepique AP. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27; PMID:20525400; http://dx.doi.org/10.1186/1471-2172-11-27
   PubMed Web of Science ®Google Scholar
• Mansilla C, Berraondo P, Durantez M, Martinez M, Casares N, Arribillaga L, Rudilla F, Fioravanti J, Lozano T, Villanueva L et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int J Cancer 2012; 131:641-51; PMID:21898393; http://dx.doi.org/10.1002/ijc.26412
   PubMed Web of Science ®Google Scholar
• Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196:541-9; PMID:12186845; http://dx.doi.org/10.1084/jem.20020732
   PubMed Web of Science ®Google Scholar
• Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martinez M, Durantez M, Mansilla C, Prieto J et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 2011; 71:3214-24; PMID:21402711; http://dx.doi.org/10.1158/0008-5472.CAN-10-3259
   PubMed Web of Science ®Google Scholar
• Halak BK, Maguire HC, Jr., Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59:911-7; PMID:10029084
   PubMed Web of Science ®Google Scholar
• Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63:2150-7; PMID:12727833
   PubMed Web of Science ®Google Scholar
• Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, Hua F, Lin H, Cai WF, Xie WJ et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009; 4:e6520; PMID:19654875; http://dx.doi.org/10.1371/journal.pone.0006520
   PubMed Web of Science ®Google Scholar
• Samarasinghe R, Tailor P, Tamura T, Kaisho T, Akira S, Ozato K. Induction of an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor signaling. J Interferon Cytokine Res 2006; 26:893-900; PMID:17238832; http://dx.doi.org/10.1089/jir.2006.26.893
   PubMed Web of Science ®Google Scholar
• Chang J, Kunkel SL, Chang CH. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci U S A 2009; 106:18327-32; PMID:19815506; http://dx.doi.org/10.1073/pnas.0905815106
   PubMed Web of Science ®Google Scholar
• Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, Gorman DM, Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012; 72:3570-81; PMID:22581824; http://dx.doi.org/10.1158/0008-5472.CAN-12-0721
   PubMed Web of Science ®Google Scholar
• Fu C, Liang X, Cui W, Ober-Blobaum JL, Vazzana J, Shrikant PA, Lee KP, Clausen BE, Mellman I, Jiang A. Beta-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Proc Natl Acad Sci U S A 2015; 112:2823-8; PMID:25730849; http://dx.doi.org/10.1073/pnas.1414167112
   PubMed Web of Science ®Google Scholar
• Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, Durantez M, Llopiz D, Sarobe P, Borras-Cuesta F et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007; 178:748-56; PMID:17202335; http://dx.doi.org/10.4049/jimmunol.178.2.748
   PubMed Web of Science ®Google Scholar